To view its chart on StockEdge, click on the link given here
Sun Pharma Advanced Research Company – Highlights
Sun Pharma Advanced Research Company (SPARC) is trading at Rs 220.35, up by 19.24% on the BSE. The stock is up 64.07% in last one year as compared to a 68.27% spurt in S&P BSE 500 and a 61.05% spurt in the S&P Bse Healthcare.
In the past one month, the stock has zoomed 31.20% while the benchmark Sensex shed 0.18% in the same period.
SPARC stated in a regulatory filing on May 9, 2021, that its board of directors will meet on May 12, 2021, to consider and evaluate proposals for raising funds in one or more tranches through the issuance of equity shares or securities/warrants convertible into equity shares of the company, via permissible modes including Preferential Issue, subject to the receipt of necessary approvals.
Separately, the company announced that its board of directors will meet on Monday, May 17, 2021, to review and approve the audited financial results for the quarter and fiscal year ended March 31, 2021.
Sun Pharma Advanced Research Company (SPARC) is a clinical stage bio-pharmaceutical company which is focused on continuously improving the patient care standards globally, through innovation in therapeutics and delivery. The company was formed in 2007 through a demerger from SUN PHARMA, which is a global leader in speciality generics.
The company is engaged in the pharmaceutical research and development. The core focus of the company is innovation and new product development for the global markets.
SPARC works on research and development programmes for new chemical entities (NCEs) or molecules, as well as novel drug delivery systems (NDDS).